PhUSE is delighted to announce that the forthcoming Computational Science Symposium with the Food and Drug Administration is open for registration.
This meeting is a unique opportunity to be informed of the latest updates and current initiatives from the FDA, industry, and academia. This is the 3rd Annual Meeting and will build on the progress made at previous events. There will be opportunities to establish collaborative working groups that address current challenges relating to the access and review of data. The ability to enhance current models to efficiently acquire, store, and analyze the data will be at the heart of the meeting agenda.
PhUSE is delighted to confirm that Charles Cooper, MD, and Steve Wilson, DrPH, of the FDA will be welcoming delegates to the Symposium alongside other representatives of CDER & CBER. In addition, a representative from CDISC will be presenting the latest updates to the data standards models. The program will then be organised into six working groups which will allow delegates to work together to discuss real world issues and how to solve them. . The working groups’ steering committee has been meeting regularly to develop an overall process and structure for the groups. Each group has co‐leads that have produced a high level list of potential topics for discussion. Unlike other forums, this event is a ‘hands‐on’ meeting that will enable those who work most closely with clinical data to debate, comment on and develop new innovative working solutions to some of theindustry’s challenges.
Ben Szilagyi , PhUSE Industry Links Director stated, “This is a great opportunity for our industry to share our expertise, know‐how, and energy to come up with novel solutions for improving the product development process. We are excited to partner with the FDA on these working groups and are looking forward to a great event.”
For registration, please follow the link: http://www.phuse.eu/ssreg.aspx
PhUSE is an independent, not‐for‐profit organization run by volunteers. Since its inception, PhUSE has expanded from its roots as a conference for European Statistical Programmers, to a global platform for the discussion of topics encompassing the work of Data Managers, Biostatisticians, Statistical Programmers, and eClinical IT professionals.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.